CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, today announced that management will host a conference call at 8:30 a.m. ET on June 15, 2018 to discuss interim clinical data from adult patients with relapsed or refractory follicular lymphoma who are receiving tazemetostat in the company’s ongoing Phase 2 study. This conference call is taking place after an oral data presentation that same day at the European Hematology Association (EHA) in Stockholm.

To participate in the call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 4869637. A live webcast will be available in the investor section of the company’s website at www.epizyme.com. The webcast will be archived on the website for 60 days.

About Epizyme, Inc.
Epizyme, Inc. is a clinical-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company is also developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.

Contacts

Media:
Erin Graves, Epizyme, Inc.
media@epizyme.com
(617) 500-0615

Investors:
Jason Fredette, Epizyme, Inc.  
ir@epizyme.com  
(617) 500-0623